Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 19;42(7):1107–1117. doi: 10.1038/s41587-023-01945-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Genentech, Inc. and Adaptive Biotechnologies Corp. 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a,b, A*11:01 monoallelic cells were engineered to express doxycycline (dox)-inducible full-length (FL) KRAS mutant proteins (G12C, G12D and G12V). These were compared against an A*11:01 monoallelic cell line containing the no-linker polyantigen cassette. a, Absolute amount of KRAS wild-type (WT) and mutant proteins in the cell lysate by targeted MS. b, Copies per cell of presented KRAS 9-mer (VVGAXGVGK) and 10-mer (VVVGAXGVGK) neoepitopes as measured by A*11:01 monomers containing heavy synthetic neoepitope peptides spiked in before affinity purification and targeted MS. c, Targeted immunopeptidomic analysis of neoepitopes in cell lines that endogenously express both KRAS and A*11:01. Two neoantigens for KRAS G12C (VVGACGVGK and VVVGACGVGK) and KRAS G12D (VVGADGVGK and VVVGADGVGK) were analyzed in cell lines that harbor KRAS G12C (HOP62 and NCIH2030), G12D (HuCCT1 and SNU601) or G12V (SW527). These neoepitopes are either novel or were described previously in non-endogenous systems. ‘Treated’ samples were treated with interferon-gamma.